Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Adverum Biotechnologies, Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$1.74 - $2.4 $153,629 - $211,903	-88,293 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$2.08 - $3.6 $5,441 - $9,417	2,616 Added 3.05%	88,293 $192,000
Q2 2021 Aug 06, 2021	BUY	$3.36 - $10.56 $190,797 - $599,649	56,785 Added 196.54%	85,677 $300,000
Q1 2021 May 06, 2021	BUY	$9.26 - $14.36 $84,367 - $130,833	9,111 Added 46.06%	28,892 $285,000
Q4 2020 Feb 09, 2021	BUY	$9.84 - $14.26 $100,102 - $145,066	10,173 Added 105.88%	19,781 $214,000
Q3 2020 Nov 10, 2020	SELL	$10.3 - $21.64 $638 - $1,341	-62 Reduced 0.64%	9,608 $99,000
Q2 2020 Aug 06, 2020	SELL	$8.53 - $25.64 $72,812 - $218,863	-8,536 Reduced 46.89%	9,670 $202,000
Q1 2020 May 11, 2020	BUY	$7.98 - $16.32 $27,203 - $55,634	3,409 Added 23.04%	18,206 $178,000
Q4 2019 Feb 05, 2020	SELL	$5.12 - $12.22 $1,940 - $4,631	-379 Reduced 2.5%	14,797 $172,000
Q3 2019 Nov 12, 2019	BUY	$5.24 - $15.89 $12,796 - $38,803	2,442 Added 19.18%	15,176 $83,000
Q2 2019 Aug 08, 2019	BUY	$5.1 - $11.89 $64,943 - $151,407	12,734 New	12,734 $151,000
Q4 2018 Feb 08, 2019	SELL	$2.87 - $5.92 $66,804 - $137,799	-23,277 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$4.5 - $7.6 $104,746 - $176,905	23,277 New	23,277 $141,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account